Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

Today, Benzinga 's options scanner spotted 33 uncommon options trades for Merck & Co. This isn't normal. The overall ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Value Investing Subreddit Page by CompanyCharts. In this article, we will summarize the bulls’ thesis on MRK. Merck & Co., Inc. (MRK)’s ...

The stock's fall snapped a four-day winning streak.

Analysts were effusive about Merus’ new HNSCC data, writing that petosemtamab could “become the standard of care” in the ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Investors with a lot of money to spend have taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s (NYSE:MRK) Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced ...